25 XP   0   0   10

Synmosa Biopharma
Buy, Hold or Sell?

Let's analyse Synmosa together

PenkeI guess you are interested in Synmosa Biopharma. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Synmosa Biopharma. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Synmosa Biopharma

I send you an email if I find something interesting about Synmosa Biopharma.

Quick analysis of Synmosa (30 sec.)










What can you expect buying and holding a share of Synmosa? (30 sec.)

How much money do you get?

How much money do you get?
NT$0.00
When do you have the money?
1 year
How often do you get paid?
66.7%

What is your share worth?

Current worth
NT$21.05
Expected worth in 1 year
NT$24.82
How sure are you?
85.7%

+ What do you gain per year?

Total Gains per Share
NT$3.77
Return On Investment
9.9%

For what price can you sell your share?

Current Price per Share
NT$38.10
Expected price per share
NT$37.25 - NT$40.50
How sure are you?
50%

1. Valuation of Synmosa (5 min.)




Live pricePrice per Share (EOD)

NT$38.10

Intrinsic Value Per Share

NT$3.69 - NT$4.07

Total Value Per Share

NT$24.74 - NT$25.12

2. Growth of Synmosa (5 min.)




Is Synmosa growing?

Current yearPrevious yearGrowGrow %
How rich?$248.6m$196.4m$33.2m14.5%

How much money is Synmosa making?

Current yearPrevious yearGrowGrow %
Making money$4.5m$6.1m-$1.5m-34.3%
Net Profit Margin11.5%18.5%--

How much money comes from the company's main activities?

3. Financial Health of Synmosa (5 min.)




What can you expect buying and holding a share of Synmosa? (5 min.)

Welcome investor! Synmosa's management wants to use your money to grow the business. In return you get a share of Synmosa.

What can you expect buying and holding a share of Synmosa?

First you should know what it really means to hold a share of Synmosa. And how you can make/lose money.

Speculation

The Price per Share of Synmosa is NT$38.10. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Synmosa.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Synmosa, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is NT$21.05. Based on the TTM, the Book Value Change Per Share is NT$0.94 per quarter. Based on the YOY, the Book Value Change Per Share is NT$0.36 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is NT$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Synmosa.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 NT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per Share
Usd Eps0.010.0%0.010.0%0.020.0%0.010.0%0.010.0%
Usd Book Value Change Per Share0.030.1%0.030.1%0.010.0%0.010.0%0.030.1%
Usd Dividend Per Share0.000.0%0.000.0%0.010.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.030.1%0.030.1%0.020.1%0.020.0%0.030.1%
Usd Price Per Share1.19-1.27-1.08-0.94-0.93-
Price to Earnings Ratio21.79-27.35-21.56-23.07-28.74-
Price-to-Total Gains Ratio36.03-20.26-80.40-59.71-56.98-
Price to Book Ratio1.84-2.16-2.11-1.96-1.99-
Price-to-Total Gains Ratio36.03-20.26-80.40-59.71-56.98-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.16967
Number of shares854
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.030.01
Usd Total Gains Per Share0.030.02
Gains per Quarter (854 shares)24.7315.78
Gains per Year (854 shares)98.9263.12
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
109989144953
201981882899116
3029728742148179
4039638655197242
5049548569246305
6059458483296368
7069268397345431
80791782111394494
90890881125443557
100989980139493620

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%19.01.00.095.0%20.01.00.095.2%20.01.00.095.2%
Book Value Change Per Share3.01.00.075.0%8.04.00.066.7%14.06.00.070.0%15.06.00.071.4%15.06.00.071.4%
Dividend per Share0.00.04.00.0%7.00.05.058.3%13.00.07.065.0%14.00.07.066.7%14.00.07.066.7%
Total Gains per Share3.01.00.075.0%10.02.00.083.3%17.03.00.085.0%18.03.00.085.7%18.03.00.085.7%

Fundamentals of Synmosa

About Synmosa Biopharma

Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand name in Taiwan. It offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company provides its products in various forms, such as effervescent tablets, granules, nasal sprays, metered dosed inhalers, hormones, and other forms. It also offers contract manufacturing services. In addition, it exports its products to South Africa, China, Hong Kong, Thailand, Singapore, Malaysia, Vietnam, Myanmar, Cambodia, Peru, Costa Rica, and Nicaragua. Synmosa Biopharma Corporation was incorporated in 1980 and is based in Taipei, Taiwan.

Fundamental data was last updated by Penke on 2024-04-16 21:54:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Synmosa Biopharma.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Synmosa earns for each NT$1 of revenue.

  • Above 10% is considered healthy but always compare Synmosa to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 12.8% means that NT$0.13 for each NT$1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Synmosa Biopharma:

  • The MRQ is 12.8%. The company is making a huge profit. +2
  • The TTM is 11.5%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ12.8%TTM11.5%+1.2%
TTM11.5%YOY18.5%-6.9%
TTM11.5%5Y12.7%-1.1%
5Y12.7%10Y12.2%+0.5%
1.1.2. Return on Assets

Shows how efficient Synmosa is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Synmosa to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.5% Return on Assets means that Synmosa generated NT$0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Synmosa Biopharma:

  • The MRQ is 1.5%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.3%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.5%TTM1.3%+0.2%
TTM1.3%YOY1.9%-0.6%
TTM1.3%5Y1.1%+0.2%
5Y1.1%10Y1.1%+0.0%
1.1.3. Return on Equity

Shows how efficient Synmosa is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Synmosa to the Drug Manufacturers - Specialty & Generic industry mean.
  • 2.5% Return on Equity means Synmosa generated NT$0.03 for each NT$1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Synmosa Biopharma:

  • The MRQ is 2.5%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.4%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.5%TTM2.4%+0.2%
TTM2.4%YOY4.0%-1.6%
TTM2.4%5Y2.4%0.0%
5Y2.4%10Y2.3%+0.1%

1.2. Operating Efficiency of Synmosa Biopharma.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Synmosa is operating .

  • Measures how much profit Synmosa makes for each NT$1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Synmosa to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated NT$0.00  for each NT$1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Synmosa Biopharma:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM6.1%-6.1%
TTM6.1%YOY10.4%-4.4%
TTM6.1%5Y7.1%-1.1%
5Y7.1%10Y6.8%+0.3%
1.2.2. Operating Ratio

Measures how efficient Synmosa is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.46 means that the operating costs are NT$1.46 for each NT$1 in net sales.

Let's take a look of the Operating Ratio trends of Synmosa Biopharma:

  • The MRQ is 1.463. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.467. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.463TTM1.467-0.004
TTM1.467YOY1.481-0.013
TTM1.4675Y1.559-0.092
5Y1.55910Y1.560-0.002

1.3. Liquidity of Synmosa Biopharma.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Synmosa is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.14 means the company has NT$2.14 in assets for each NT$1 in short-term debts.

Let's take a look of the Current Ratio trends of Synmosa Biopharma:

  • The MRQ is 2.143. The company is able to pay all its short-term debts. +1
  • The TTM is 1.836. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.143TTM1.836+0.307
TTM1.836YOY1.802+0.034
TTM1.8365Y1.572+0.264
5Y1.57210Y1.542+0.030
1.3.2. Quick Ratio

Measures if Synmosa is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Synmosa to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.83 means the company can pay off NT$0.83 for each NT$1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Synmosa Biopharma:

  • The MRQ is 0.831. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.638. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.831TTM0.638+0.193
TTM0.638YOY0.6380.000
TTM0.6385Y0.497+0.141
5Y0.49710Y0.488+0.009

1.4. Solvency of Synmosa Biopharma.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Synmosa assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Synmosa to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.31 means that Synmosa assets are financed with 30.9% credit (debt) and the remaining percentage (100% - 30.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Synmosa Biopharma:

  • The MRQ is 0.309. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.363. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.309TTM0.363-0.054
TTM0.363YOY0.411-0.048
TTM0.3635Y0.421-0.058
5Y0.42110Y0.420+0.001
1.4.2. Debt to Equity Ratio

Measures if Synmosa is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Synmosa to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 54.1% means that company has NT$0.54 debt for each NT$1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Synmosa Biopharma:

  • The MRQ is 0.541. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.700. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.541TTM0.700-0.159
TTM0.700YOY0.887-0.187
TTM0.7005Y0.963-0.262
5Y0.96310Y0.962+0.001

2. Market Valuation of Synmosa Biopharma

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every NT$1 in earnings Synmosa generates.

  • Above 15 is considered overpriced but always compare Synmosa to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 21.79 means the investor is paying NT$21.79 for every NT$1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Synmosa Biopharma:

  • The EOD is 21.475. Based on the earnings, the company is fair priced.
  • The MRQ is 21.785. Based on the earnings, the company is fair priced.
  • The TTM is 27.353. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD21.475MRQ21.785-0.310
MRQ21.785TTM27.353-5.568
TTM27.353YOY21.557+5.796
TTM27.3535Y23.074+4.279
5Y23.07410Y28.737-5.663
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Synmosa Biopharma:

  • The EOD is 27.005. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 27.395. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 9.553. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD27.005MRQ27.395-0.390
MRQ27.395TTM9.553+17.842
TTM9.553YOY34.493-24.941
TTM9.5535Y1,231.101-1,221.548
5Y1,231.10110Y1,171.223+59.877
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Synmosa is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 1.84 means the investor is paying NT$1.84 for each NT$1 in book value.

Let's take a look of the Price to Book Ratio trends of Synmosa Biopharma:

  • The EOD is 1.810. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.836. Based on the equity, the company is underpriced. +1
  • The TTM is 2.158. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.810MRQ1.836-0.026
MRQ1.836TTM2.158-0.322
TTM2.158YOY2.110+0.048
TTM2.1585Y1.965+0.193
5Y1.96510Y1.985-0.020
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Synmosa Biopharma compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.0730.943+14%0.360+198%0.470+128%1.002+7%
Book Value Per Share--21.04919.440+8%16.626+27%15.578+35%15.391+37%
Current Ratio--2.1431.836+17%1.802+19%1.572+36%1.542+39%
Debt To Asset Ratio--0.3090.363-15%0.411-25%0.421-26%0.420-26%
Debt To Equity Ratio--0.5410.700-23%0.887-39%0.963-44%0.962-44%
Dividend Per Share----0%0.290-100%0.132-100%0.131-100%
Eps--0.4440.386+15%0.519-15%0.310+43%0.297+49%
Free Cash Flow Per Share--0.3530.157+124%0.290+22%0.107+231%0.089+297%
Free Cash Flow To Equity Per Share--0.3530.195+81%0.214+65%0.128+176%0.091+289%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--4.067--------
Intrinsic Value_10Y_min--3.688--------
Intrinsic Value_1Y_max--0.794--------
Intrinsic Value_1Y_min--0.780--------
Intrinsic Value_3Y_max--2.090--------
Intrinsic Value_3Y_min--2.001--------
Intrinsic Value_5Y_max--3.032--------
Intrinsic Value_5Y_min--2.840--------
Market Cap14663013600.000-1%14874684400.00015963968693.788-7%13592103673.000+9%11758012250.878+27%11709307465.102+27%
Net Profit Margin--0.1280.115+11%0.185-31%0.127+1%0.122+5%
Operating Margin---0.061-100%0.104-100%0.071-100%0.068-100%
Operating Ratio--1.4631.4670%1.481-1%1.559-6%1.560-6%
Pb Ratio1.810-1%1.8362.158-15%2.110-13%1.965-7%1.985-8%
Pe Ratio21.475-1%21.78527.353-20%21.557+1%23.074-6%28.737-24%
Price Per Share38.100-1%38.65041.476-7%35.317+9%30.551+27%30.424+27%
Price To Free Cash Flow Ratio27.005-1%27.3959.553+187%34.493-21%1231.101-98%1171.223-98%
Price To Total Gains Ratio35.514-1%36.02720.265+78%80.405-55%59.712-40%56.981-37%
Quick Ratio--0.8310.638+30%0.638+30%0.497+67%0.488+70%
Return On Assets--0.0150.013+15%0.019-21%0.011+31%0.011+36%
Return On Equity--0.0250.024+6%0.040-36%0.024+5%0.023+9%
Total Gains Per Share--1.0730.943+14%0.649+65%0.602+78%1.133-5%
Usd Book Value--248697783.500229706640.700+8%196433781.150+27%184060988.865+35%181853173.586+37%
Usd Book Value Change Per Share--0.0330.029+14%0.011+198%0.014+128%0.031+7%
Usd Book Value Per Share--0.6460.597+8%0.510+27%0.478+35%0.473+37%
Usd Dividend Per Share----0%0.009-100%0.004-100%0.004-100%
Usd Eps--0.0140.012+15%0.016-15%0.010+43%0.009+49%
Usd Free Cash Flow--4167340.8001858593.350+124%3422451.350+22%1259198.875+231%1050207.529+297%
Usd Free Cash Flow Per Share--0.0110.005+124%0.009+22%0.003+231%0.003+297%
Usd Free Cash Flow To Equity Per Share--0.0110.006+81%0.007+65%0.004+176%0.003+289%
Usd Market Cap450154517.520-1%456652811.080490093838.899-7%417277582.761+9%360970976.102+27%359475739.179+27%
Usd Price Per Share1.170-1%1.1871.273-7%1.084+9%0.938+27%0.934+27%
Usd Profit--5240397.9004565335.600+15%6133023.425-15%3657881.975+43%3511328.581+49%
Usd Revenue--41059837.80039453299.125+4%33665343.700+22%28367239.010+45%27917528.890+47%
Usd Total Gains Per Share--0.0330.029+14%0.020+65%0.018+78%0.035-5%
 EOD+4 -4MRQTTM+28 -5YOY+23 -125Y+30 -510Y+28 -7

3.2. Fundamental Score

Let's check the fundamental score of Synmosa Biopharma based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1521.475
Price to Book Ratio (EOD)Between0-11.810
Net Profit Margin (MRQ)Greater than00.128
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.831
Current Ratio (MRQ)Greater than12.143
Debt to Asset Ratio (MRQ)Less than10.309
Debt to Equity Ratio (MRQ)Less than10.541
Return on Equity (MRQ)Greater than0.150.025
Return on Assets (MRQ)Greater than0.050.015
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Synmosa Biopharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.158
Ma 20Greater thanMa 5038.890
Ma 50Greater thanMa 10038.832
Ma 100Greater thanMa 20038.895
OpenGreater thanClose38.300
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in TWD. All numbers in thousands.

Summary
Total Assets11,728,587
Total Liabilities3,627,682
Total Stockholder Equity6,709,514
 As reported
Total Liabilities 3,627,682
Total Stockholder Equity+ 6,709,514
Total Assets = 11,728,587

Assets

Total Assets11,728,587
Total Current Assets4,539,322
Long-term Assets7,189,265
Total Current Assets
Cash And Cash Equivalents 918,559
Short-term Investments 736,330
Net Receivables 1,023,855
Inventory 1,598,224
Other Current Assets 2,125
Total Current Assets  (as reported)4,539,322
Total Current Assets  (calculated)4,279,093
+/- 260,229
Long-term Assets
Property Plant Equipment 5,557,087
Goodwill 62,286
Intangible Assets 496,563
Long-term Assets Other 113,144
Long-term Assets  (as reported)7,189,265
Long-term Assets  (calculated)6,229,080
+/- 960,185

Liabilities & Shareholders' Equity

Total Current Liabilities2,118,421
Long-term Liabilities1,509,261
Total Stockholder Equity6,709,514
Total Current Liabilities
Short Long Term Debt 957,858
Accounts payable 420,287
Other Current Liabilities 10,240
Total Current Liabilities  (as reported)2,118,421
Total Current Liabilities  (calculated)1,388,385
+/- 730,036
Long-term Liabilities
Long term Debt 1,400,043
Capital Lease Obligations Min Short Term Debt81,958
Long-term Liabilities Other 531
Long-term Liabilities  (as reported)1,509,261
Long-term Liabilities  (calculated)1,482,532
+/- 26,729
Total Stockholder Equity
Retained Earnings 813,915
Total Stockholder Equity (as reported)6,709,514
Total Stockholder Equity (calculated)813,915
+/- 5,895,599
Other
Capital Stock4,014,149
Common Stock Shares Outstanding 384,856
Net Debt 1,439,342
Net Invested Capital 9,067,415
Net Working Capital 2,420,901
Property Plant and Equipment Gross 5,557,087



Balance Sheet

Currency in TWD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
> Total Assets 
7,544,637
8,251,544
8,580,050
8,698,369
8,729,958
8,867,394
10,398,316
10,356,327
10,377,467
10,333,696
10,221,329
10,121,464
10,316,783
10,409,186
10,638,078
11,186,668
11,202,516
11,401,928
12,555,320
11,335,214
11,728,587
11,728,58711,335,21412,555,32011,401,92811,202,51611,186,66810,638,07810,409,18610,316,78310,121,46410,221,32910,333,69610,377,46710,356,32710,398,3168,867,3948,729,9588,698,3698,580,0508,251,5447,544,637
   > Total Current Assets 
1,846,454
1,911,025
2,274,586
2,253,376
2,311,848
2,500,475
2,705,409
2,943,426
2,982,219
2,996,222
2,933,133
2,875,220
3,098,879
3,239,416
3,551,879
3,911,614
4,008,370
4,121,392
5,294,230
4,086,200
4,539,322
4,539,3224,086,2005,294,2304,121,3924,008,3703,911,6143,551,8793,239,4163,098,8792,875,2202,933,1332,996,2222,982,2192,943,4262,705,4092,500,4752,311,8482,253,3762,274,5861,911,0251,846,454
       Cash And Cash Equivalents 
447,081
352,846
575,115
548,701
465,102
616,800
694,777
567,854
638,345
633,070
721,886
736,888
868,166
813,804
1,079,224
1,049,096
1,087,650
1,094,141
2,182,658
802,383
918,559
918,559802,3832,182,6581,094,1411,087,6501,049,0961,079,224813,804868,166736,888721,886633,070638,345567,854694,777616,800465,102548,701575,115352,846447,081
       Short-term Investments 
0
15,708
20,396
19,488
105,000
26,621
7,529
6,816
107,009
106,861
101,530
103,344
120,263
277,201
203,566
417,783
331,683
377,198
305,779
419,201
736,330
736,330419,201305,779377,198331,683417,783203,566277,201120,263103,344101,530106,861107,0096,8167,52926,621105,00019,48820,39615,7080
       Net Receivables 
613,710
579,341
581,038
647,365
701,273
761,276
664,184
697,303
718,840
745,744
789,079
721,631
810,106
842,596
981,355
1,024,249
1,146,093
1,148,338
1,172,059
1,019,045
1,023,855
1,023,8551,019,0451,172,0591,148,3381,146,0931,024,249981,355842,596810,106721,631789,079745,744718,840697,303664,184761,276701,273647,365581,038579,341613,710
       Inventory 
669,909
776,793
849,454
858,108
948,736
1,002,801
1,187,009
1,305,872
1,199,438
1,186,764
1,255,115
1,245,535
1,214,184
1,226,060
1,205,256
1,335,978
1,383,688
1,429,274
1,502,240
1,535,521
1,598,224
1,598,2241,535,5211,502,2401,429,2741,383,6881,335,9781,205,2561,226,0601,214,1841,245,5351,255,1151,186,7641,199,4381,305,8721,187,0091,002,801948,736858,108849,454776,793669,909
       Other Current Assets 
55,572
336
464
108
49,693
48,446
95,237
306,555
271,353
267,906
4,612
8,282
35,054
30,104
16,146
14,910
2,636
7,393
59,252
1,044
2,125
2,1251,04459,2527,3932,63614,91016,14630,10435,0548,2824,612267,906271,353306,55595,23748,44649,69310846433655,572
   > Long-term Assets 
0
6,340,519
6,305,464
6,444,993
6,418,110
6,366,919
7,692,907
7,412,901
7,395,248
7,337,474
7,288,196
7,246,244
7,217,904
7,169,770
7,086,199
7,275,054
7,194,146
7,280,536
7,261,090
7,249,014
7,189,265
7,189,2657,249,0147,261,0907,280,5367,194,1467,275,0547,086,1997,169,7707,217,9047,246,2447,288,1967,337,4747,395,2487,412,9017,692,9076,366,9196,418,1106,444,9936,305,4646,340,5190
       Property Plant Equipment 
4,097,845
4,893,869
4,898,557
4,889,445
4,898,407
4,920,076
6,055,348
5,790,079
5,788,350
5,766,444
5,738,923
5,705,451
5,662,301
5,618,084
5,586,296
5,675,032
5,637,953
5,632,249
5,631,434
5,598,376
5,557,087
5,557,0875,598,3765,631,4345,632,2495,637,9535,675,0325,586,2965,618,0845,662,3015,705,4515,738,9235,766,4445,788,3505,790,0796,055,3484,920,0764,898,4074,889,4454,898,5574,893,8694,097,845
       Goodwill 
24,808
24,808
24,808
24,808
0
0
0
0
0
0
0
0
0
7,273
0
64,940
71,080
71,080
71,080
71,080
62,286
62,28671,08071,08071,08071,08064,94007,27300000000024,80824,80824,80824,808
       Long Term Investments 
536,724
442,540
458,381
581,803
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000581,803458,381442,540536,724
       Intangible Assets 
299,464
586,022
565,871
545,759
0
0
0
0
0
0
0
0
0
485,605
0
531,665
496,799
555,290
539,694
522,106
496,563
496,563522,106539,694555,290496,799531,6650485,605000000000545,759565,871586,022299,464
       Long-term Assets Other 
0
93,232
87,487
170,947
94,605
83,908
74,398
87,478
92,894
41,819
41,331
51,115
50,335
62,075
61,119
55,312
63,609
65,921
58,734
121,085
113,144
113,144121,08558,73465,92163,60955,31261,11962,07550,33551,11541,33141,81992,89487,47874,39883,90894,605170,94787,48793,2320
> Total Liabilities 
3,059,397
3,734,867
4,141,460
4,234,875
3,917,016
4,082,620
4,518,481
4,464,974
4,422,847
4,488,775
4,349,766
4,289,338
4,221,421
4,366,703
4,259,908
4,662,164
4,553,695
4,870,483
4,946,493
3,647,187
3,627,682
3,627,6823,647,1874,946,4934,870,4834,553,6954,662,1644,259,9084,366,7034,221,4214,289,3384,349,7664,488,7754,422,8474,464,9744,518,4814,082,6203,917,0164,234,8754,141,4603,734,8673,059,397
   > Total Current Liabilities 
1,980,192
2,543,608
2,942,119
2,619,498
2,198,784
1,713,343
1,747,233
1,535,887
1,559,667
1,706,101
1,770,829
1,837,513
1,888,877
1,849,630
1,905,571
2,095,749
2,322,715
2,804,877
2,804,903
2,214,795
2,118,421
2,118,4212,214,7952,804,9032,804,8772,322,7152,095,7491,905,5711,849,6301,888,8771,837,5131,770,8291,706,1011,559,6671,535,8871,747,2331,713,3432,198,7842,619,4982,942,1192,543,6081,980,192
       Short-term Debt 
789,748
1,929,581
2,155,804
1,930,039
1,549,471
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000001,549,4711,930,0392,155,8041,929,581789,748
       Short Long Term Debt 
789,748
1,929,581
2,155,804
1,930,039
1,549,471
1,000,458
861,032
494,470
631,615
657,327
667,871
738,026
764,756
689,850
670,756
1,015,230
1,184,987
1,442,116
1,371,311
1,053,193
957,858
957,8581,053,1931,371,3111,442,1161,184,9871,015,230670,756689,850764,756738,026667,871657,327631,615494,470861,0321,000,4581,549,4711,930,0392,155,8041,929,581789,748
       Accounts payable 
185,236
178,996
270,565
297,449
306,393
324,234
259,485
307,411
184,260
221,290
281,554
262,480
249,584
292,407
309,224
437,942
446,163
412,378
487,553
443,086
420,287
420,287443,086487,553412,378446,163437,942309,224292,407249,584262,480281,554221,290184,260307,411259,485324,234306,393297,449270,565178,996185,236
       Other Current Liabilities 
154,157
5,647
5,542
5,132
126,010
194,021
243,350
201,257
220,663
316,743
258,644
254,933
190,249
377,360
383,360
314,342
9,479
643,359
564,919
13,224
10,240
10,24013,224564,919643,3599,479314,342383,360377,360190,249254,933258,644316,743220,663201,257243,350194,021126,0105,1325,5425,647154,157
   > Long-term Liabilities 
0
1,191,259
1,199,341
1,615,377
1,718,232
2,369,277
2,771,248
2,929,087
2,863,180
2,782,674
2,578,937
2,451,825
2,332,544
2,517,073
2,354,337
2,566,415
2,230,980
2,065,606
2,141,590
1,432,392
1,509,261
1,509,2611,432,3922,141,5902,065,6062,230,9802,566,4152,354,3372,517,0732,332,5442,451,8252,578,9372,782,6742,863,1802,929,0872,771,2482,369,2771,718,2321,615,3771,199,3411,191,2590
       Capital Lease Obligations 
0
19,025
16,916
17,852
15,652
13,881
11,819
12,091
10,667
9,045
7,500
5,764
13,498
12,024
19,086
73,177
65,126
72,668
93,184
88,013
81,958
81,95888,01393,18472,66865,12673,17719,08612,02413,4985,7647,5009,04510,66712,09111,81913,88115,65217,85216,91619,0250
       Long-term Liabilities Other 
0
1,197
1,197
1,197
33,403
25,809
1,747
24,456
20,654
20,090
19,526
18,961
20,067
886
18,966
12,582
12,617
12,377
329
330
531
53133032912,37712,61712,58218,96688620,06718,96119,52620,09020,65424,4561,74725,80933,4031,1971,1971,1970
> Total Stockholder Equity
3,216,726
3,196,492
3,175,397
3,278,996
3,483,670
3,509,211
4,330,446
4,408,887
4,500,092
4,428,502
4,503,165
4,584,558
4,705,519
4,693,786
4,995,614
5,136,720
5,311,815
5,239,207
6,410,149
6,532,238
6,709,514
6,709,5146,532,2386,410,1495,239,2075,311,8155,136,7204,995,6144,693,7864,705,5194,584,5584,503,1654,428,5024,500,0924,408,8874,330,4463,509,2113,483,6703,278,9963,175,3973,196,4923,216,726
   Common Stock
1,974,760
1,974,760
1,974,760
2,260,484
2,441,685
2,441,685
2,642,205
2,826,833
2,808,183
2,808,183
2,808,183
3,131,342
3,131,342
3,131,342
3,136,842
3,437,007
3,437,007
3,437,007
3,687,007
0
0
003,687,0073,437,0073,437,0073,437,0073,136,8423,131,3423,131,3423,131,3422,808,1832,808,1832,808,1832,826,8332,642,2052,441,6852,441,6852,260,4841,974,7601,974,7601,974,760
   Retained Earnings 
309,886
323,236
15,495
29,925
113,896
158,533
580,977
655,591
713,489
693,654
770,909
518,045
613,433
617,218
725,279
838,152
1,004,598
934,624
787,467
643,878
813,915
813,915643,878787,467934,6241,004,598838,152725,279617,218613,433518,045770,909693,654713,489655,591580,977158,533113,89629,92515,495323,236309,886
   Accumulated Other Comprehensive Income 000000000000000000000
   Capital Surplus 000000000000000000000
   Treasury Stock000000000000000000000



Balance Sheet

Currency in TWD. All numbers in thousands.




Cash Flow

Currency in TWD. All numbers in thousands.




Income Statement

Currency in TWD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue5,140,495
Cost of Revenue-3,020,566
Gross Profit2,119,9292,119,929
 
Operating Income (+$)
Gross Profit2,119,929
Operating Expense-4,520,159
Operating Income620,336-2,400,230
 
Operating Expense (+$)
Research Development210,905
Selling General Administrative1,286,622
Selling And Marketing Expenses0
Operating Expense4,520,1591,497,527
 
Net Interest Income (+$)
Interest Income11,410
Interest Expense-67,257
Other Finance Cost-0
Net Interest Income-55,847
 
Pretax Income (+$)
Operating Income620,336
Net Interest Income-55,847
Other Non-Operating Income Expenses0
Income Before Tax (EBT)601,558620,336
EBIT - interestExpense = -67,257
594,832
662,089
Interest Expense67,257
Earnings Before Interest and Taxes (EBIT)0668,815
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax601,558
Tax Provision-196,389
Net Income From Continuing Ops405,169405,169
Net Income594,832
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net055,847
 

Technical Analysis of Synmosa
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Synmosa. The general trend of Synmosa is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Synmosa's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Synmosa Biopharma.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 40.05 < 40.20 < 40.50.

The bearish price targets are: 37.50 > 37.40 > 37.25.

Tweet this
Synmosa Biopharma Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Synmosa Biopharma. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Synmosa Biopharma Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Synmosa Biopharma. The current macd is -0.25893623.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Synmosa price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Synmosa. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Synmosa price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Synmosa Biopharma Daily Moving Average Convergence/Divergence (MACD) ChartSynmosa Biopharma Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Synmosa Biopharma. The current adx is 22.16.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Synmosa shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Synmosa Biopharma Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Synmosa Biopharma. The current sar is 39.27.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Synmosa Biopharma Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Synmosa Biopharma. The current rsi is 42.16. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Synmosa Biopharma Daily Relative Strength Index (RSI) ChartSynmosa Biopharma Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Synmosa Biopharma. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Synmosa price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Synmosa Biopharma Daily Stochastic Oscillator ChartSynmosa Biopharma Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Synmosa Biopharma. The current cci is -70.69729948.

Synmosa Biopharma Daily Commodity Channel Index (CCI) ChartSynmosa Biopharma Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Synmosa Biopharma. The current cmo is -20.70081623.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Synmosa Biopharma Daily Chande Momentum Oscillator (CMO) ChartSynmosa Biopharma Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Synmosa Biopharma. The current willr is -76.47058824.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Synmosa is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Synmosa Biopharma Daily Williams %R ChartSynmosa Biopharma Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Synmosa Biopharma.

Synmosa Biopharma Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Synmosa Biopharma. The current atr is 0.46009049.

Synmosa Biopharma Daily Average True Range (ATR) ChartSynmosa Biopharma Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Synmosa Biopharma. The current obv is 729,090,262.

Synmosa Biopharma Daily On-Balance Volume (OBV) ChartSynmosa Biopharma Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Synmosa Biopharma. The current mfi is 29.44.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Synmosa Biopharma Daily Money Flow Index (MFI) ChartSynmosa Biopharma Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Synmosa Biopharma.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-02MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-16BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-25STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Synmosa Biopharma Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Synmosa Biopharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.158
Ma 20Greater thanMa 5038.890
Ma 50Greater thanMa 10038.832
Ma 100Greater thanMa 20038.895
OpenGreater thanClose38.300
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Synmosa with someone you think should read this too:
  • Are you bullish or bearish on Synmosa? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Synmosa? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Synmosa Biopharma

I send you an email if I find something interesting about Synmosa Biopharma.


Comments

How you think about this?

Leave a comment

Stay informed about Synmosa Biopharma.

Receive notifications about Synmosa Biopharma in your mailbox!